This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily multiple-dose administration of odanacatib (MK0822).

Inclusion Criteria:

• Subject is a male between the ages of 18 and 45 or a female less than or equal to 70 years of age
• Females must be past menopause
• Subject is a nonsmoker
• Subject is willing to avoid excessive alcohol consumption during the study and is willing to avoid alcohol entirely for 24 hours prior to drug administration and during PK sampling
• Subject is willing to refrain from consuming grapefruit or grapefruit juice

Exclusion Criteria:

• Subject has a history of multiple/severe allergies to drugs or food
• Subject has donated blood within 4 weeks of starting the study
• Subject has a history of metabolic bone disease, urolithiasis, or bisphosphonate treatment
• Subject has any infections or any condition leading to immune problems, including HIV
• Subject regularly uses illegal drugs
• Subject consumes more than 3 alcoholic beverages per day
• Subject drinks 4 or more caffeinated beverages per day
• Subject uses any prescription or nonprescription medications